Patents by Inventor Ella Evron

Ella Evron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aberrantly methylated genes as markers of breast malignancy
    Patent number: 7858317
    Abstract: The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RAR?), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: December 28, 2010
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Saraswati Sukumar, Ella Evron, William C. Dooley, Nicoletta Sacchi, Nancy Davidson, Mary Jo Fackler
  • Aberrantly Methylated Genes as Markers of Breast Malignancy
    Publication number: 20090136944
    Abstract: The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RAR?), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy.
    Type: Application
    Filed: October 9, 2008
    Publication date: May 28, 2009
    Inventors: Saraswati Sukumar, Ella Evron, William C. Dooley, Nicoletta Sacchi, Nancy Davidson, Mary Jo Fackler
  • Aberrantly methylated genes as markers of breast malignancy
    Publication number: 20050191640
    Abstract: The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RAR?), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy.
    Type: Application
    Filed: June 18, 2004
    Publication date: September 1, 2005
    Inventors: Saraswati Sukumar, Ella Evron, William Dooley, Nicoletta Sacchi, Nancy Davidson, Mary Fackler
  • Aberrantly methylated genes as markers of breast malignancy
    Patent number: 6835541
    Abstract: The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RAR&bgr;), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy.
    Type: Grant
    Filed: January 28, 2002
    Date of Patent: December 28, 2004
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Saraswati Sukumar, Ella Evron, William C. Dooley, Nicoletta Sacchi, Nancy Davidson, Mary Jo Fackler
  • Aberrantly methylated genes as markers of breast malignancy
    Patent number: 6756200
    Abstract: The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RAR&bgr;), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, and combinations of such genes serve as markers of breast malignancy.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: June 29, 2004
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Saraswati Sukumar, Ella Evron, William C. Dooley, Nicoletta Sacchi, Nancy Davidson
  • Aberrantly methylated genes as markers of breast malignancy
    Publication number: 20030138783
    Abstract: The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RAR&bgr;), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy.
    Type: Application
    Filed: January 28, 2002
    Publication date: July 24, 2003
    Inventors: Saraswati Sukumar, Ella Evron, William C. Dooley, Nicoletta Sacchi, Nancy Davidson, Mary Jo Fackler
  • Aberrantly methylated genes as markers of breast malignancy
    Publication number: 20030017454
    Abstract: The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RAR&bgr;), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, and combinations of such genes serve as markers of breast malignancy.
    Type: Application
    Filed: January 26, 2001
    Publication date: January 23, 2003
    Inventors: Saraswati Sukumar, Ella Evron, William C. Dooley, Nicoletta Sacchi, Nancy Davidson